Figure 2.
Differences in the percentages of naïve and central memory CD4 T cells were observed in patients with CSU treated with omalizumab when compared to those treated with NID or to HD. Percentages of (A) naïve, (B) central memory, (C) effector memory, and (D) effector CD4 T cells in peripheral blood of HD, NID, and CSU patients under omalizumab treatment. CSU, chronic spontaneous urticaria; HD, healthy donors (n = 50); NID, non-immunomodulatory drugs (n = 27); OZB, omalizumab (n = 24).
